Find information on thousands of medical conditions and prescription drugs.

Efavirenz

Efavirenz (brand names Sustiva® and Stocrin®) is non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of high active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. more...

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine, tenofovir or stavudine is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV tranmission. The usual adult dose is 600 mgs once a day taken on an empty stomach at bedtime.

History

Efavirenz was approved by the Food and Drug Administration (FDA) on Sep 21, 1998, making it the fourteenth approved antiretroviral drug.

Drug interactions

  • Efavirenz is metabolized in the liver, and possesses both inhibitory and inducing effects on the 3A4 isoform of the cytochrome P450 system. This means efavirenz may interact with other drugs metabolized in the liver, requiring either increased or decreased dosages.
  • Efavirenz lowers blood levels of most protease inhibitors. Dosages of amprenavir, atazanavir, or indinavir may need to be increased. The blood levels of saquinavir are dramatically lowered, so that the two drugs cannot be used simultaneously.
  • St. John's Wort and garlic supplements may decrease efavirenz blood levels.

Side effects

  • Psychiatric symptoms, including insomnia, confusion, memory loss, and depression, are common.
  • rash nausea dizziness and headache may occur
  • efavirenz can cause birth defects
  • safety in children has not been established
  • use of efavirenz can cause a false positive in some urine tests for marijuana

Mechanism of action

Efavirenz is chemically described as (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one. Its empirical formula is C14H9ClF3NO2. Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It is practically insoluble in water (<10 µg/mL).



Read more at Wikipedia.org


[List your site here Free!]


Trial of efavirenz vs. nevirapine for HIV ends in a draw. (Multicenter, International Study). : An article from: Family Practice News $5.95 Efavirenz and nevirapine: which baffles HIV best? (Head-to-Head Trial). : An article from: Internal Medicine News $5.95
Efavirenz vs. nevirapine for HIV trial inconclusive: head-to-head trial a draw.(Dermatoligic Theraphy) : An article from: Skin & Allergy News $5.95

Drug racing: gene tied to HIV-drug response - Efavirenz
A genetic mutation seven times as common in blacks as in whites increases the odds that people taking a common HIV medicine will surfer side effects ...
FDA approves once-daily efavirenz formulation, revised labeling
The FDA sent the following email on February 4: The FDA approved on February 1, 2002, a new formulation of Sustiva (efavirenz), a non nucleoside reverse ...
EFAVIRENZ - Sustiva
The 200 mg capsules of efavirenz are gold-colored, reverse-printed with "SUSTIVA" on the body and imprinted with "200 mg" on the cap. Other dose formulations ...
A review of abacvir and efavirenz: New antiretroviral drugs to treat HIV-1 infection
The standard of care for the treatment of HIV type 1 infection includes a combination of highly active antiretroviral drugs (HAART) with the goal of suppressing ...
New tests would help lower perinatal transmission
The HIV epidemic continues to expand in Africa and beyond, and will continue to infect women as well as men. Tens of millions of people are already infected worldwide, more than a million of them i
TMC 125: new results, large phase III trial begins
TMC125 (also spelled TMC-125, TMC 125, or etravirine), by Tibotec Pharmaceuticals Ltd., based in Cork, Ireland and now part of Johnson & Johnson, ...
Failure of tenofovir + abacavir + 3TC combination; full report published, more insight
In 2003 researchers stopped a clinical trial abruptly when they found that a combination of three drugs that seemed likely to work well together failed ...
CCR5 entry inhibitor problems: no clear answers yet
Three different experimental drugs that inhibit HIV by the same mechanism (blocking its use of the CCR5 co-receptor) have run into problems recently ...

Home Contact Resources Exchange Links ebay